Faster, more con­ve­nient Op­di­vo dos­ing sched­ules gives Bris­tol-My­ers added edge in bat­tle of the PD-1 block­busters with Mer­ck

Look­ing to hold off a re­lent­less as­sault by Mer­ck on the top slot in the mega-block­buster bat­tle of the PD-1/L1 check­points, Bris­tol-My­ers Squibb $BMY just scored a cou­ple of new ad­vances that will help its star ther­a­py Op­di­vo re­tain its heavy­weight ti­tle in the field.

Bris­tol-My­ers ob­tained an FDA ap­proval for a once-every-4 weeks dose of the PD-1, with a 480 mg dose re­plac­ing two 240 mg dos­es. And reg­u­la­tors gave their thumbs up to a 30-minute in­fu­sion of Op­di­vo, cut­ting their old time in half.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER